Valuation: Genexine, Inc.

Market Cap 243B 159M 139M 127M 119M 225M 15.11B 229M 1.53B 595M 7.43B 596M 583M 25.59B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 161M 140M 129M 120M 228M 15.29B 232M 1.55B 602M 7.52B 603M 590M 25.9B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-15 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
25-09-30 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-09-22 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-03-07 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
24-09-30 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
24-07-04 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
24-06-25 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
24-05-14 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
23-11-14 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-10-23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
23-08-31 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day+1.43%
1 week+8.26%
Current month-1.39%
1 month-28.65%
3 months-46.22%
6 months-49.08%
Current year-46.85%
1 week 2,250
Extreme 2250
2,670
1 month 2,210
Extreme 2210
3,290
Current year 2,210
Extreme 2210
7,490
1 year 2,210
Extreme 2210
7,490
3 years 2,210
Extreme 2210
12,300
5 years 2,210
Extreme 2210
75,538.46
10 years 2,210
Extreme 2210
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 2025-03-25
Chief Executive Officer 61 2023-01-26
Corporate Officer/Principal 49 2021-12-31
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 2022-03-28
Director/Board Member 61 2023-01-26
Date Insider Type Main position Quantity % Market Cap.
24-10-21Others 563,723 1.3580%
24-10-21Others 156,632 0.3773%
24-10-21Others

Chief Executive Officer

1,691,165 4.0741%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+8.26%-50.15%-75.03% 73.99M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.73%+7.11%+43.80%+122.69% 24.56B
Weighted average by Cap. +2.46%+6.47%+58.29%+136.91%

Financials

2022 2023
Net sales 16.14B 10.54M 9.22M 8.47M 7.9M 14.98M 1B 15.2M 102M 39.53M 493M 39.58M 38.73M 1.7B 4.43B 2.89M 2.53M 2.32M 2.17M 4.11M 275M 4.17M 27.89M 10.84M 135M 10.86M 10.62M 466M
Net income -55.97B -36.57M -31.97M -29.38M -27.39M -51.94M -3.48B -52.73M -353M -137M -1.71B -137M -134M -5.9B -66.87B -43.69M -38.19M -35.1M -32.72M -62.06M -4.16B -63M -421M -164M -2.04B -164M -160M -7.05B
Net Debt 62.14B 40.6M 35.49M 32.62M 30.4M 57.67M 3.87B 58.54M 392M 152M 1.9B 152M 149M 6.55B 2.94B 1.92M 1.68M 1.55M 1.44M 2.73M 183M 2.77M 18.56M 7.21M 90.05M 7.22M 7.07M 310M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
26-07-03 ₩2,490.00 +1.43% 103,512
26-07-02 ₩2,455.00 -3.35% 114,038
26-07-01 ₩2,540.00 +0.59% 115,503
26-06-30 ₩2,525.00 -4.72% 148,089
26-06-29 ₩2,650.00 +15.22% 224,586
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock